Our results show a higher frequency of TP53 mutations among the BRCA1 methylated tumours compared with the non-methylated tumours or 38.5% (5 of 13) and 17.2% (22 of 128), respectively (P = 0.1299, OR = 3.0, 95%CI = 0.9–10.1). The gene discussed is TP53; the disease is neoplasm.